Basal Cell Carcinoma Presenting as a Nonhealing Wound

Owen, William R.; Thurs, Kathy

doi:10.1097/01.asw.0000358640.76210.49

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2) Recruitment of monocytes or macrophages to the tumor site A variety of studies demonstrate that anticancer therapies induce the recruitment of monocytes to the tumor sites where chemotherapy-damaged cells are localized, which monocytes consider as persistent nonhealing wounds to be repaired. 95 In this case, tumor-infiltrating macrophages initiate the regenerative program that supports the proliferation of cancer cells. 96 Thus, it was shown that chemotherapy, ionizing radiation, and the vascular disrupting agent combretastatin A4-P cause the increased production of the mononuclear phagocyte growth factor CSF-1 and the chemokines CCL2 and CXCL12 that can trigger monocyte recruitment and TAM accumulation in tumor sites.…”

Section: ) Changes In Macrophage Phenotype During Chemotherapy Treatmentmentioning

confidence: 99%

Interaction of tumor-associated macrophages and cancer chemotherapy

et al. 2019

View full text Add to dashboard Cite

It has been recently recognized that the tumor microenvironment (TME) is an essential factor that defines the efficiency of chemotherapy. The local TME, consisting of immune cells with diverse phenotypes and functions, can strongly modulate the response to chemotherapy. Tumor-associated macrophages (TAMs) that display pronounced heterogeneity and phenotypic plasticity are the major innate immune component in the microenvironment of solid tumors. In our review, we elucidate the complex role of TAMs in the progression of different types of solid tumors, summarize the current knowledge about the effects of different anticancer chemotherapeutic agents on monocytes/macrophages, and describe the mechanisms of chemotherapy resistance mediated by TAMs.

show abstract

Section: ) Changes In Macrophage Phenotype During Chemotherapy Treatmentmentioning

confidence: 99%

Interaction of tumor-associated macrophages and cancer chemotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Many anticancer drugs mimic a battlefield, inducing damaged/dying cells and recruiting monocytes to the tumor bed as a nonhealing wound must be repaired [ 34 , 36 ]. The recruitment of immature macrophages in the tumor may reduce tumor growth, as shown by Laoui et al based on clinical and experimental data [ 37 ], although in the TME macrophages tend to switch to the M2 phenotype.…”

Section: Chemotherapymentioning

confidence: 99%

How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review

et al. 2022

View full text Add to dashboard Cite

Chemotherapy is much more effective in immunocompetent mice than in immunodeficient ones, and it is now acknowledged that an efficient immune system is necessary to optimize chemotherapy activity and efficacy. Furthermore, chemotherapy itself may reinvigorate immune response in different ways: by targeting cancer cells through the induction of cell stress; the release of damage signals and the induction of immunogenic cell death; by targeting immune cells; inhibiting immune suppressive cells and/or activating immune effector cells; and by targeting the host physiology through changes in the balance of gut microbiome. All these effects acting on immune and non-immune components interfere with the tumor microenvironment, leading to the different activity and efficacy of treatments. This article describes the correlation between chemotherapy and the immune changes induced in the tumor microenvironment. Our ultimate aim is to pave the way for the identification of the best drugs or combinations, the doses, the schedules and the right sequences to use when chemotherapy is combined with immunotherapy.

show abstract